Reata Pharma Shares Are Trading Higher After Filing US Application In Alport Syndrome-Related Kidney Disease

Reata Pharmaceuticals Inc (NASDAQ: RETA) has submitted a marketing application to the FDA for bardoxolone methyl (bardoxolone) to treat chronic kidney disease caused by Alport syndrome.

• Alport syndrome is a rare, genetic form of kidney disease caused by mutations in the genes encoding type IV collagen, a major structural component of the kidney's glomerular basement membrane.
• The kidneys of patients with Alport syndrome progressively lose the capacity to filter waste products out of the blood, leading to end-stage kidney disease. 
• In November last year, the company announced positive Phase 3 CARDINAL study results.
• Data demonstrated that patients treated with bardoxolone experienced a statistically significant improvement in kidney function measured by eGFR at Week 100 and Week 104, compared to patients treated with placebo.
• Price Action: RETA shares are up 5.4% at $128.81 in market trading hours on the last check Monday.